Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 8, 2013 (14 years ago)

Bucalsep

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent; Cetylpyridinum Chloride

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

BUCALSEP (R) ORAL SOLUTION, (Benzocaine, 600 mg, Cetylpyridinum Chloride 30 mg, Menthol 45 mg Zinc Chloride 30 mg), 1 Fl. Oz. (30 mL), Manufactured for GIL PHARMACEUTICAL CORP, PONCE, PUERTO RICO 00717-1565 -- NDC 58552-103-01

Affected NDC 58552-0103-01

Compare with the code on your package — it is the most precise check available.

Drug: Zinc

Recalling firm
Hi-Tech Pharmacal Co., Inc.
NDC code
58552-103-01
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-418-2013 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zinc recalls

See all
Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026

Other recalls by Hi-Tech Pharmacal Co., Inc.

All 2013 recalls
Class II · Moderate risk

HydrOXYzine Hydrochloride Oral Solution

Failed Impurity/Degradation Specification; out-of-specification result for one individual unknown impurity at the 24-month room temperature stability test station.

Terminated Temperature excursion Hi-Tech Pharmacal Co., Inc. NDC 50383-796-16 D-0048-2015
Class III · Low risk

Acyclovir Oral Suspension

Failed Stability Specification; product viscosity and or pH are below specification.

Terminated Stability / shelf life Hi-Tech Pharmacal Co., Inc. NDC 50383-810-16 D-389-2014
Class III · Low risk

Clobetasol Propionate Cream

Labeling: Label Mix-up; some cartons labeled as Clobetasol Propionate Cream USP contain tubes labeled as Clobetasol Propionate Gel USP. The actual product in the tube is Clobetasol Propionate Cream USP

Terminated Labeling / mix-up Hi-Tech Pharmacal Co., Inc. NDC 50383-267-15 D-888-2013